{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:19:24Z","timestamp":1751429964157,"version":"3.41.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jceh.2025.102541","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T08:09:02Z","timestamp":1742371742000},"page":"102541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Tenofovir Plus Entecavir Combination Therapy Versus Tenofovir Monotherapy in Chronic Hepatitis B Virus Patients With Resistance or Partial Response to Entecavir: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8452-4052","authenticated-orcid":false,"given":"Syed H.","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakshi","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-2834","authenticated-orcid":false,"given":"Hareesha R.","family":"Bharadwaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joecelyn K.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1041-3501","authenticated-orcid":false,"given":"Medha S.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2361-0816","authenticated-orcid":false,"given":"Muhtasim","family":"Fuad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0347-4733","authenticated-orcid":false,"given":"Aditya","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyal","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1794-2569","authenticated-orcid":false,"given":"Arkadeep","family":"Dhali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4921-8794","authenticated-orcid":false,"given":"Harishankar","family":"Gopakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2025.102541_bib1","doi-asserted-by":"crossref","first-page":"773","DOI":"10.15585\/mmwr.mm6728a2","article-title":"Access to treatment for hepatitis B virus infection \u2014 worldwide, 2016","volume":"67","author":"Hutin","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2 suppl 1","key":"10.1016\/j.jceh.2025.102541_bib2","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1002\/hep.20956","article-title":"Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005","volume":"43","author":"Yim","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2025.102541_bib3","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1002\/hep.22885","article-title":"Side effects of long-term oral antiviral therapy for hepatitis B","volume":"49","author":"Fontana","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2025.102541_bib4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1743-422X-8-72","article-title":"Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis","volume":"8","author":"Zhang","year":"2011","journal-title":"Virol J"},{"key":"10.1016\/j.jceh.2025.102541_bib5","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2025.102541_bib6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2025.102541_bib7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2025.102541_bib8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2025.102541_bib9","first-page":"305","article-title":"Effectiveness of entecavir treatment and predictive factors for virologic response","volume":"106","author":"Preda","year":"2014","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.jceh.2025.102541_bib10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000360399","article-title":"Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations","volume":"57","author":"Yim","year":"2014","journal-title":"Intervirology"},{"key":"10.1016\/j.jceh.2025.102541_bib11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jvh.12613","article-title":"No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment","volume":"24","author":"Liu","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jceh.2025.102541_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2025.102541_bib13","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"n71","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jceh.2025.102541_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jceh.2025.102541_bib15","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1007\/s10620-012-2402-2","article-title":"Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders","volume":"57","author":"Yip","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jceh.2025.102541_bib16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/jvh.12368","article-title":"Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir","volume":"22","author":"Lu","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jceh.2025.102541_bib17","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/gutjnl-2014-308353","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial","volume":"65","author":"Lim","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2025.102541_bib18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3350\/cmh.2017.0003","article-title":"Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir","volume":"23","author":"Jeon","year":"2017","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jceh.2025.102541_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/jvh.12623","article-title":"Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance","volume":"24","author":"Lee","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jceh.2025.102541_bib20","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1111\/bcp.13330","article-title":"A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study","volume":"83","author":"Yuan","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jceh.2025.102541_bib21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/jmv.25608","article-title":"Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir","volume":"92","author":"Wang","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.jceh.2025.102541_bib22","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1186\/s12879-021-06554-1","article-title":"Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients","volume":"21","author":"Shang","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jceh.2025.102541_bib23","first-page":"165","article-title":"Efficacy comparison of rescue therapies between TDF monotherapy and TDF-ETV combination therapy in CHB patients who failed to be rescued with ETV","volume":"21","author":"Zhong-bin","year":"2016","journal-title":"Chin Hepatol"},{"key":"10.1016\/j.jceh.2025.102541_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12072-012-9385-0","article-title":"Are we ready to use the hepatitis B surface antigen level to guide peginterferon treatment in HBeAg-negative chronic hepatitis B?","volume":"7","author":"Chan","year":"2013","journal-title":"Hepatol Int."},{"key":"10.1016\/j.jceh.2025.102541_bib25","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.clinthera.2017.07.015","article-title":"Comparison of the efficacy of tenofovir versus tenofovir plus entecavir in the treatment of chronic hepatitis B in patients with poor efficacy of entecavir: a systematic review and meta-analysis","volume":"39","author":"Chen","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.jceh.2025.102541_bib26","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/liv.13059","article-title":"Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study","volume":"36","author":"Park","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2025.102541_bib27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jhep.2019.02.006","article-title":"Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients","volume":"70","author":"Park","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.102541_bib28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12072-009-9140-3","article-title":"HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B","volume":"3","author":"Liaw","year":"2009","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jceh.2025.102541_bib29","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688325000416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688325000416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T18:14:24Z","timestamp":1751393664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688325000416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0973688325000416"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2025.102541","relation":{},"ISSN":["0973-6883"],"issn-type":[{"type":"print","value":"0973-6883"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Tenofovir Plus Entecavir Combination Therapy Versus Tenofovir Monotherapy in Chronic Hepatitis B Virus Patients With Resistance or Partial Response to Entecavir: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2025.102541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102541"}}